Welcome to our dedicated page for Immunocore Holdings Plc SEC filings (Ticker: IMCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Immunocore’s SEC disclosures can feel like decoding lab results—dense R&D footnotes, milestone revenue clauses, and risk factors unique to T cell receptor science. If you have ever asked, “How do I find Immunocore insider trading Form 4 transactions?” or “What does Immunocore report in its 10-K about the ImmTAX pipeline?”, you are not alone.
Stock Titan solves that problem. Our AI-powered summaries translate every Immunocore annual report 10-K into plain English, highlight key cash-burn metrics in the quarterly earnings report 10-Q filing, and surface 8-K material events explained within minutes of hitting EDGAR. Real-time alerts track Immunocore Form 4 insider transactions so you can see executive stock moves before the market digests them. No more combing through hundreds of pages—our platform answers natural questions like “understanding Immunocore SEC documents with AI” directly inside the filing.
Want deeper insight? Compare R&D spend by program, monitor royalty-bearing sales of KIMMTRAK, or review Immunocore proxy statement executive compensation—all in one place. Whether you need Immunocore earnings report filing analysis for valuation models or Immunocore executive stock transactions Form 4 for sentiment checks, you’ll find every document—from S-1s to 20-F equivalents—indexed, searchable, and summarized. It’s Immunocore SEC filings explained simply, with the context biotech investors need.
Insider notice to sell 135,000 American Depositary Shares (ADS) of Immunocore Holdings plc (IMCR) is reported on Form 144. The shares are to be sold through J.P. Morgan Securities LLC on 09/10/2025 with an aggregate market value of $4,939,650. The filing shows the ADS were acquired and will be sold on 09/10/2025 via a stock option exercise, with payment made in cash. The issuer has 50,387,068 ADS outstanding per the form. The filer reports no other securities sold in the past three months and certifies no undisclosed material adverse information.
Primecap Management Co/CA reports beneficial ownership of 3,772,234 ADRs of Immunocore Holdings plc, representing 7.51% of the class. The filing shows Primecap is an investment adviser organized in the United States and holds sole voting power for 3,746,574 shares and sole dispositive power for 3,772,234 shares. The statement clarifies these securities are held in the ordinary course of business and were not acquired to change or influence control of the issuer. The document identifies the ADR class and provides the filer’s principal business address.
Filing: Schedule 13G/A (Amendment No. 5) reporting for Immunocore Holdings plc (CUSIP 45258D105).
Key facts: Wellington Management Group LLP and affiliated entities report beneficial ownership of 5,132,898 shares of Immunocore common stock (reported as 10.2% / 10.22% of the class). Reported ownership shows no sole voting or dispositive power; shared voting power is reported as 4,958,998 and shared dispositive power as 5,132,898. The filing notes these shares are owned of record by clients of Wellington investment advisers and identifies Vanguard Health Care Fund as an exception referenced in Item 6. The issuer address and filer addresses are included; the filing is signed by Taisia Lowe on 08/05/2025.
FAQ
What is the current stock price of Immunocore Holdings Plc (IMCR)?
What is the market cap of Immunocore Holdings Plc (IMCR)?
